Gilead has gotten a new HIV preventive treatment, Yeztugo, approved, which consists of two injections a year, promising more effective prevention.
Lara Maior
Current Affairs
Foto Gilead Pharma
Always see our news on Google
Yeztugo, a drug developed by Gilead, has been authorized in the United States as a preventive treatment against HIV. It requires only two injections a year, unlike current treatments that require daily pills. While the treatment could revolutionize the fight against the AIDS epidemic, cost remains a crucial issue, with an estimated annual price tag of about $25,000. UNAIDS director Winnie Byanyima emphasized the importance of making the drug affordable to have a real impact in the fight against AIDS.
Sources
Tratament promiţător împotriva HIV-SIDA. Producătorii promit prețuri accesibil
Statele Unite autorizează un nou tratament preventiv, foarte promiţător, împotriva HIV, virusul care cauzează SIDA
FDA approves first twice-yearly injection that prevents HIV infection
US approves promising preventive HIV treatment
Groundbreaking twice-a-year HIV drug that could stop transmission approved
Latest News
23:14
The mayor of Iași announced the cessation of street lighting at night due to the energy crisis. The measure will save approximately 10 MWh per night.
22:41
A SpaceX rocket out of control will crash on the Moon, forming a 27-meter crater.
22:01
Greece is facing new wildfires. A suburb of Athens has already been evacuated.
21:26
Traian Băsescu: Bolojan needs to rebuild the coalition with PSD for the good of the country
21:05
The Romanian Army has been mobilized to protect the operation of the Cernavodă Nuclear Power Plant, carrying out hydrographic measurements on the Danube.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
